Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation

JHOP - August 2023 Vol 13, No 4 - FDA Oncology Update
NEW INDICATIONS

On June 20, 2023, the FDA approved a new indication for talazoparib (Talzenna; Pfizer), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide for homologous recombination repair (HRR) gene mutation–positive, metastatic castration-resistant prostate cancer (CRPC). The FDA granted this application priority review.

This is the first PARP inhibitor approved for use with a current standard of care (enzalutamide) for adults with metastatic CRPC and HRR gene mutation.

Talazoparib was initially approved as monotherapy for locally advanced or metastatic HER2-negative breast cancer with deleterious or suspected deleterious germline BRCA mutation.

The current approval was based on the results of the phase 3 TALAPRO-2 (NCT03395197) study, a randomized, double-blind, placebo-controlled, multicohort clinical trial of patients with metastatic CRPC and HRR gene mutation. These patients were randomized 1:1 to enzalutamide 160 mg daily plus talazoparib 0.5 mg or placebo daily.

The eligibility criteria included having a previous orchiectomy or receiving gonadotropin-releasing hormone (GnRH) analogs. Patients were excluded if they had previous systemic therapy for metastatic CRPC, but previous treatment with cytochrome (CY) P17 inhibitors or docetaxel for metastatic castration-sensitive prostate cancer was permitted. The trial stratified randomization by previous treatment with a CYP17 inhibitor or docetaxel.

The study investigators prospectively assessed multiple HRR genes using circulating tumor DNA–based next-generation sequencing assays and/or tumor tissue.

There was a significant improvement in radiographic progression-free survival (PFS), which was the major efficacy measure, for talazoparib with enzalutamide compared with placebo plus enzalutamide in patients with the HRR mutation (median, not reached vs 13.8 months; hazard ratio, 0.45; 95% confidence interval [CI], 0.33-0.61; P<.0001). According to the results of an exploratory analysis by BRCA mutation status, the hazard ratio for radiographic PFS was 0.20 (95% CI, 0.11-0.36) in patients with metastatic CRPC and the BRCA mutation (n=155) and 0.72 (95% CI, 0.49-1.07) in patients who had HRR-positive metastatic CRPC without the BRCA mutation.

The most common (≥10%) adverse reactions, including laboratory abnormalities, were decreased hemoglobin, decreased neutrophils, decreased lymphocytes, fatigue, decreased platelets, decreased calcium, nausea, decreased appetite, decreased sodium, decreased phosphate, fractures, decreased magnesium, dizziness, increased bilirubin, decreased potassium, and dysgeusia. In TALAPRO-2, 39% of the total patients with metastatic CRPC who received talazoparib plus enzalutamide (199/511) needed a blood transfusion, including 22% who needed multiple transfusions, and 2 patients were diagnosed with myelodysplastic syndrome or acute myeloid leukemia.

“Despite treatment advancement in metastatic castration-resistant prostate cancer, the disease can progress quickly, and many patients may only receive one line of therapy….For patients with [metastatic] CRPC harboring HRR genetic alterations, outcomes are even worse,” said Neeraj Agarwal, MD, FASCO, Professor and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, University of Utah, and global lead study investigator. “The FDA’s approval of the talazoparib and enzalutamide combination…represents a treatment option deserving of excitement and attention.”

The recommended dose of talazoparib is 0.5 mg orally, once daily, with enzalutamide (recommended dose, 160 mg orally once daily) until disease progression or unacceptable adverse events. This combination treatment should be accompanied by a concurrent GnRH analog or previous bilateral orchiectomy.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: